reports
Pacira BioSciences to Present Real-World Data on EXPAREL® Showing Redu...
Pacira BioSciences to Present Real-World Data on EXPAREL® Showing Reduced Cost of Care at Orthopaedic Research Society 2026 Annual Meeting -- Studies highlight reduced total cost of care and select healthcare resource utilization outcomes in total knee arthroplasty (TKA) and spinal fusion -- BRISBANE, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced findings from two real-world studies evaluating the economic benefit...
Pacira BioSciences Reaffirms Commitment to Shareholder Value Creation
Pacira BioSciences Reaffirms Commitment to Shareholder Value Creation -- Issues Statement in Response to DOMA’s Nomination of Director Candidates -- -- No Shareholder Action Required at This Time -- BRISBANE, Calif., March 11, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today confirmed that DOMA Perpetual Capital Management LLC (“DOMA”) has nominated three director candidates to stand for election to the Pacira Board of Directors (the “Board”)...
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule...
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BRISBANE, Calif., March 06, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today announced the granting of inducement awards on March 3, 2026 to three new employees under Pacira’s Amended and Restated 2014 Inducement Plan (the “Inducement Plan”) as a material inducement to each employee’s entry into employment with the company. In accordance with Nasdaq Listing Rule 5635(c)(4), ...
Pacira BioSciences to Participate in Fireside Chat at the Barclays 28t...
Pacira BioSciences to Participate in Fireside Chat at the Barclays 28th Annual Global Healthcare Conference BRISBANE, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it will participate in an analyst-led fireside chat at the Barclays 28th Annual Global Healthcare Conference at 2:30 PM ET on Wednesday, March 11, 2026 in Miami. Live audio of the event can be accessed by visiting the “Events” page of the company’s ...
Pacira BioSciences Presents Two Real-World Studies from Its Innovation...
Pacira BioSciences Presents Two Real-World Studies from Its Innovations in Genicular Outcomes Registry (IGOR) -- Studies highlight the clinical effectiveness of EXPAREL for total knee arthroplasty and long-term pain management with ioveraº for patients with osteoarthritis (OA) of the knee -- -- Data presented at the American Academy of Orthopedic Surgeons 2026 Annual Meeting -- BRISBANE, Calif., March 02, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of p...
Pacira BioSciences Reports Fourth Quarter and Full-Year 2025 Financial...
Pacira BioSciences Reports Fourth Quarter and Full-Year 2025 Financial Results — Record-high EXPAREL sales driven by volume growth of 7 percent, marking strongest fourth quarter performance in three years — — Conference call today at 4:30 p.m. ET — BRISBANE, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today reported financial results for the fourth quarter and full-year of 2025. “2025 was a year of disciplined execution for P...
Pacira to Report 2025 Financial Results on Thursday February 26, 2026
Pacira to Report 2025 Financial Results on Thursday February 26, 2026 BRISBANE, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it will report its fourth quarter and year ended December 31, 2025 financial results after the close of the U.S. markets on Thursday February 26, 2026. Following the release, the company will host a live conference call and webcast at 4:30 p.m. ET. For listeners who wish to participate ...
Pacira Highlights New NOPAIN Act Survey Data Conducted by Voices for N...
Pacira Highlights New NOPAIN Act Survey Data Conducted by Voices for Non-Opioid Choices BRISBANE, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies, today highlighted new survey findings released by the Voices for Non-Opioid Choices (Voices) coalition following the first year of the Non-Opioids Prevent Addiction (“NOPAIN”) Act. Made up of more than 250 organizations dedicated to preventing opioid addiction before it starts, Voices is the nation’s leading nonpartisan coa...
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule...
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BRISBANE, Calif., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today announced the granting of inducement awards on February 3, 2026 to 14 new employees under Pacira’s Amended and Restated 2014 Inducement Plan (the “Inducement Plan”) as a material inducement to each employee’s entry into employment with the company. In accordance with Nasdaq Listing Rule 5635(c)(4), t...
Pacira BioSciences Appoints Samit Hirawat, M.D., to Board of Directors
Pacira BioSciences Appoints Samit Hirawat, M.D., to Board of Directors -- Veteran Executive Brings More Than 25 Years of Clinical Development and Industry Expertise -- BRISBANE, Calif., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced the appointment of Samit Hirawat, M.D., to its Board of Directors. This appointment increases the size of the company’s Board of Directors to 10 members. “Samit is an accomplished and widely re...
Pacira Announces Agreement with LG Chem to Make EXPAREL® Available in ...
Pacira Announces Agreement with LG Chem to Make EXPAREL® Available in Select Asian-Pacific Markets -- LG Chem becomes exclusive distributor of EXPAREL -- – Partnership expands patient access to opioid-sparing pain control and advances 5x30 strategy– BRISBANE, Calif., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced it has entered into an agreement with LG Chem designed to expand access to opioid-sparing postsurgical pain c...
Pacira Reports Preliminary Unaudited Fourth Quarter and Full-Year 2025...
Pacira Reports Preliminary Unaudited Fourth Quarter and Full-Year 2025 Revenues -- Record-high EXPAREL sales driven by volume growth of 7 percent, marking strongest fourth quarter performance in three years-- BRISBANE, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today reported preliminary, unaudited total revenue of $726.4 million for the year ended December 31, 2025, compared with $701.0 million for the year ended December 31, ...
Pacira BioSciences to Present at the 44th Annual J.P. Morgan Healthcar...
Pacira BioSciences to Present at the 44th Annual J.P. Morgan Healthcare Conferences BRISBANE, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it will present at the 44th Annual J.P. Morgan Healthcare Conference at 11:15 AM PST (2:15 PM EST) on Wednesday, January 14, 2026. Live audio of the event can be accessed by visiting the “Events” page of the company’s website at . A replay of the webcast will also be availa...
Pacira Biosciences Joins PROBE Consortium to Transform Osteoarthritis ...
Pacira Biosciences Joins PROBE Consortium to Transform Osteoarthritis Research and Care --Public-private partnership aims to improve osteoarthritis research, diagnosis and treatment----PROBE will leverage data from over 70 million individuals across multiple OA cohorts and real-world registries-- BRISBANE, Calif., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Pacira Biosciences, Inc. (NASDAQ: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today announced it has joined the PROBE (Patient Relevant Osteoarthritis endpoints using B...
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule...
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BRISBANE, Calif., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today announced the granting of inducement awards on December 1, 2025 to two new employees under Pacira’s Amended and Restated 2014 Inducement Plan (the “Inducement Plan”) as a material inducement to each employee’s entry into employment with the company. In accordance with Nasdaq Listing Rule 5635(c)(4), ...
Pacira BioSciences Announces Results From 12-Month Pilot Study Demonst...
Pacira BioSciences Announces Results From 12-Month Pilot Study Demonstrating Favorable Safety and Significant Improvements in Pain With iovera° Compared to Radiofrequency Ablation in Chronic Low Back Pain -- New data published in Pain Physician shows significant improvement in functional outcomes with iovera° ---- Fewer iovera° patients required additional spine injections after 180 days ---- No treatment-related adverse events were reported -- BRISBANE, Calif., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in its commitment to deliver inn...
Pacira BioSciences Files EXPAREL® Patent Infringement Lawsuits Against...
Pacira BioSciences Files EXPAREL® Patent Infringement Lawsuits Against The WhiteOak Group and Qilu Pharmaceutical -- Lawsuit triggers 30-month stay under the Hatch Waxman Act -- BRISBANE, Calif., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it has filed a patent infringement lawsuit in the United States District Court for the District of Delaware against The WhiteOak Group, Inc. and Qilu Pharmaceutical (Hainan) Co., ...
Pacira Biosciences Inc: 1 director
A director at Pacira Biosciences Inc sold 12,060 shares at 22.090USD and the significance rating of the trade was 51/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years ...
Pacira BioSciences to Participate in Fireside Chat at Two Upcoming Hea...
Pacira BioSciences to Participate in Fireside Chat at Two Upcoming Healthcare Conferences BRISBANE, Calif., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it will participate in an analyst-led fireside chat at the following two healthcare conferences: Jefferies London Healthcare Conference on Tuesday, November 18th at 1:30PM GMT (8:30AM ET).37th Annual Piper Sandler Healthcare Conference on Tuesday, December 2nd at 1:3...
Pacira BioSciences Reports Third Quarter 2025 Financial Results; Incre...
Pacira BioSciences Reports Third Quarter 2025 Financial Results; Increases Full-year Gross Margin Guidance -- Third quarter revenues up 6% driven by EXPAREL volume growth of 9% -- -- Several key milestones advance 5x30 path to growth and value creation -- -- Conference call today at 4:30 p.m. ET -- BRISBANE, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today reported financial results for the third quarter of 2025. Third Quart...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.